European Commission Approves Biocon’s Pebrilzo Biosimilar
On 18 November 2026, the European Commission granted Biocon Limited marketing authorisation for Pebrilzo, its pertuzumab biosimilar, to treat HER2-positive breast cancer across multiple disease stages in the European Union.
Approval and indication
Pebrilzo is a 420 mg concentrate for solution for infusion, used with trastuzumab and chemotherapy for HER2-positive early-stage, locally advanced, inflammatory and metastatic breast cancer. It is the first biosimilar to receive European Commission authorisation under the European Medicines Agency’s tailored clinical approach. The Committee for Medicinal Products for Human Use issued a positive opinion on 17 September 2026.
US approval and launch plans
The US Food and Drug Administration approved Pebrilzo, also known as pertuzumab-qcay, on 16 November 2026 for adults with HER2-positive metastatic and early breast cancer. It is Biocon’s fifth oncology biosimilar approved in both Europe and the United States. Under a global patent settlement and licence agreement with Genentech, Biocon plans to launch it in the European Union and United Kingdom in the first quarter of 2027; its licensed US launch is set for the third quarter of 2028. Biocon chief executive and managing director Shreehas Tambe said the approval strengthens the company’s oncology portfolio and commitment to affordable biologic therapies.
Important Facts for Exams
- HER2–HER3 blockade: Pertuzumab binds HER2 at its HER3-binding domain, preventing HER2–HER3 dimer formation and blocking that dimer’s signalling.
- Complementary antibody binding: Trastuzumab binds a different HER2 domain; together, the two antibodies prevent HER2 from functioning.
- Recombinant production: Pertuzumab is an IgG1 monoclonal antibody manufactured recombinantly in CHO cells.
- Reference medicine: Pebrilzo is highly similar to Perjeta, its reference product, which was authorised in the EU on 4 March 2013.